Abstract: An amino acid composition is provided that can promote fat burning, improve endurance, and reduce fatigue during, for example, marathons, and that can lessen obesity and increase stress resistance. The amino acid composition comprises 3.0 to 10.0 mass parts of aspartic acid, 2.5 to 9.0 mass parts of threonine, 2.0 to 9.5 mass parts of serine, 12.0 to 40.0 mass parts of glutamic acid, 7.0 to 20.0 mass parts of proline, 0.5 to 4.5 mass parts of glycine, 1.0 to 4.5 mass parts of alanine, 3.0 to 12.0 mass parts of valine, 0.1 to 0.8 mass part of cystine, 1.5 to 5.0 mass parts of methionine, 2.0 to 8.0 mass parts of isoleucine, 5.0 to 15.0 mass parts of leucine, 3.0 to 10.0 mass parts of tyrosine, 3.0 to 10.0 mass parts of phenylalanine, 4.0 to 15.0 mass parts of lysine, 0.8 to 4.0 mass parts of tryptophan, 1.5 to 5.0 mass parts of histidine, and 2.0 to 6.0 mass parts of arginine, wherein the total amount of these amino acids is 100 mass parts.

Abstract: The present inventors produced lotus leaf extracts, and discovered that quercetin is one of the active ingredients. As a result of treating ?3-adrenergic receptor-expressing cells and feeding diabetes model mice with quercetin and evaluating its effects, the present inventors discovered specifically that quercetin produces obesity-improving effects and antidiabetic effects by acting as a ?3-adrenergic receptor agonist.

Abstract: A compound which has the following formula (1), a process for its production, a pharmaceutical composition comprising the compound as an active ingredient, a method of treating tumor which comprises administering the compound, use of the compound as a medicine, and a microorganism capable of producing the compound. The compound of the present invention is a novel compound which has antitumor action and is useful as a medicine.

Abstract: The present inventors focused on the lotus plant and prepared lotus extracts. When ?-glucosidase and its substrate sucrose were reacted with the lotus extracts to examine the effect of adding the extracts on the enzymatic reaction, the lotus extracts were found to have ?-glucosidase inhibitory activity. Furthermore, when the lotus extract and sucrose were administered to mice and their blood glucose levels were measured, the lotus extracts were found to suppress blood glucose levels. More specifically, the present inventors discovered that the lotus extracts have ?-glucosidase inhibitory activity and can be used to control blood glucose levels.

Abstract: This invention relates to a novel compound which has a cytotoxic activity and TGF-? like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.

Abstract: This invention relates to a novel compound which has a cytotoxic activity and TGF-&bgr; like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.

Abstract: This invention relates to a novel compound which has a cytotoxic activity and TGF-&bgr; like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.

Abstract: A compound which has the following formula (1), 1

Abstract: A compound which has the following formula (1), a process for its production, a pharmaceutical composition comprising the compound as an active ingredient, a method of treating tumor which comprises administering the compound, use of the compound as a medicine, and a microorganism capable of producing the compound. The compound of the present invention is a novel compound which has antitumor action and is useful as a medicine.

Abstract: Extract of at least one selected from GAJUTSU (zedoariae rhizoma), KYOUOU (curcumae rhizoma) and ICHO leaves (ginko leaves) obtained using polar solvent, and composition containing the extract are disclosed; since the extract has an excellent effect on lowering the level of blood triglyceride, is derived from natural material and has an excellent level of safety, the extract and the composition can be used as or in drink, food or medicine.

Abstract: A substance PF1191 having an inhibitory activity to kainic acid toxicity represented by the following formula (I) which is obtained by incubating a fungus belonging to the genus Eupenicillium and isolating the product thus produced from the culture by solvent extraction, adsorption column chromatography, gel filtration, etc.

Abstract: Dihydrophenazinecarboxylic acid derivatives of the formula (I) wherein R.sup.1 represents hydrogen, linear or branched alkyl, etc., each of R.sup.2 and R.sup.3 represents hydrogen, 3-methyl-2-butenyl, etc., and each of R.sup.4 and R.sup.5 represents hydrogen, alkyl, alkenyl, aralkyl, aryl, hydroxyl, alkoxy, aryloxy, aralkyloxy, halogen, nitro, cyano, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, arylcarbonyl, etc., provided that there is no case that both of R.sup.4 and R.sup.5 are hydrogen. The dihydrophenazinecarboxylic acid derivatives are excellent in the inhibition of glutamic acid toxicity.

Abstract: Aqueous solution preparations which comprise azulene sodium sulfonate as an active ingredient and 20 w/v % or more of a polyhydric alcohol are disclosed wherein azulene sodium sulfonate is stable in the preparation for a prolonged period of time is suited for use in treating inflammation of the oral cavity and/or throat.